http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 06:23:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+Luo+Peter/26613881.html si-local-file:///var/storage/secattach/20260608/26613881.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+Luo+Peter/26613881.html Mon, 08 Jun 2026 06:23:00 -0400 ADAG O.49875626 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+Luo+Peter/26613881.html si-local-file:///var/storage/secattach/20260608/26613881.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+Luo+Peter/26613881.html Mon, 08 Jun 2026 06:23:00 -0400 ADAG O.49875626 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+WuXi+PharmaTech+Healthcare+Fund+I+L.P./26506414.html si-local-file:///var/storage/secattach/20260515/26506414.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+WuXi+PharmaTech+Healthcare+Fund+I+L.P./26506414.html Fri, 15 May 2026 16:32:00 -0400 ADAG O.49875626 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+WuXi+PharmaTech+Healthcare+Fund+I+L.P./26506414.html si-local-file:///var/storage/secattach/20260515/26506414.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+WuXi+PharmaTech+Healthcare+Fund+I+L.P./26506414.html Fri, 15 May 2026 16:32:00 -0400 ADAG O.49875626 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Press+Releases/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html <p align="left">SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.</p> <p><strong>Stifel Annual Virtual Oncology Event </strong></p> <ul type="disc"><li><strong>Format:</strong> Fireside Chat and 1x1 Meetings</li><li><strong>Date/Time:</strong> Tuesday, May 19, 2026, at 2:30 http://www.streetinsider.com/Globe+Newswire/Adagene+to+Participate+in+Two+Upcoming+Investor+Conferences/26473680.html Tue, 12 May 2026 08:30:00 -0400 A.50216777 ADAG O.49875626 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26450951.html si-local-file:///var/storage/secattach/20260507/26450951.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26450951.html Thu, 07 May 2026 11:30:00 -0400 ADAG O.49875626 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26450951.html si-local-file:///var/storage/secattach/20260507/26450951.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Adagene+Inc.+++++++++++++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26450951.html Thu, 07 May 2026 11:30:00 -0400 ADAG O.49875626 http://www.streetinsider.com/Corporate+News/Adagene+presents+trial+data+showing+muzastotug+combination+benefits/26330526.html <p>Adagene Inc. (NASDAQ: ADAG) presented clinical trial data at the American Association for Cancer Research annual meeting showing its drug muzastotug demonstrated improved response rates when combined with existing cancer therapies.</p><p>In a Phase 1b/2 study for hepatocellular carcinoma, the triple combination of muzastotug, atezolizumab and bevacizumab showed a 66.7% overall response rate compared to 32.5% for the control arm receiving only atezolizumab and bevacizumab. The study included six patients in the triple combination arm and 40 patients in the control arm.</p><p>A separate Phase 1b/2 study evaluated muzastotug combined with pembrolizumab and fruquintinib in microsatellite stable colorectal cancer patients. Results showed http://www.streetinsider.com/Corporate+News/Adagene+presents+trial+data+showing+muzastotug+combination+benefits/26330526.html Fri, 17 Apr 2026 16:01:44 -0400 ADAG http://www.streetinsider.com/FDA/Adagene+presents+trial+data+showing+muzastotug+combination+benefits/26330526.html <p>Adagene Inc. (NASDAQ: ADAG) presented clinical trial data at the American Association for Cancer Research annual meeting showing its drug muzastotug demonstrated improved response rates when combined with existing cancer therapies.</p><p>In a Phase 1b/2 study for hepatocellular carcinoma, the triple combination of muzastotug, atezolizumab and bevacizumab showed a 66.7% overall response rate compared to 32.5% for the control arm receiving only atezolizumab and bevacizumab. The study included six patients in the triple combination arm and 40 patients in the control arm.</p><p>A separate Phase 1b/2 study evaluated muzastotug combined with pembrolizumab and fruquintinib in microsatellite stable colorectal cancer patients. Results showed http://www.streetinsider.com/FDA/Adagene+presents+trial+data+showing+muzastotug+combination+benefits/26330526.html Fri, 17 Apr 2026 16:01:44 -0400 ADAG http://www.streetinsider.com/Press+Releases/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html <p align="center"><em>Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients</em></p> <p align="center"><em>Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% ORR for 10 mg/kg and 15 mg/kg, respectively) in a Phase 1b/2 trial in late-line microsatellite stable colorectal cancer (MSS CRC) patients</em></p> <p align="center"><em>New data are further http://www.streetinsider.com/Press+Releases/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html Fri, 17 Apr 2026 16:01:00 -0400 ADAG ADAG http://www.streetinsider.com/Press+Releases/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html <p align="center"><em>Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients</em></p> <p align="center"><em>Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% ORR for 10 mg/kg and 15 mg/kg, respectively) in a Phase 1b/2 trial in late-line microsatellite stable colorectal cancer (MSS CRC) patients</em></p> <p align="center"><em>New data are further http://www.streetinsider.com/Press+Releases/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html Fri, 17 Apr 2026 16:01:00 -0400 ADAG ADAG http://www.streetinsider.com/Globe+Newswire/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html <p align="center"><em>Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients</em></p> <p align="center"><em>Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% ORR for 10 mg/kg and 15 mg/kg, respectively) in a Phase 1b/2 trial in late-line microsatellite stable colorectal cancer (MSS CRC) patients</em></p> <p align="center"><em>New data are further http://www.streetinsider.com/Globe+Newswire/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html Fri, 17 Apr 2026 16:01:00 -0400 ADAG ADAG http://www.streetinsider.com/Globe+Newswire/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html <p align="center"><em>Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients</em></p> <p align="center"><em>Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% ORR for 10 mg/kg and 15 mg/kg, respectively) in a Phase 1b/2 trial in late-line microsatellite stable colorectal cancer (MSS CRC) patients</em></p> <p align="center"><em>New data are further http://www.streetinsider.com/Globe+Newswire/Adagene+Presents+Two+Posters+at+AACR+2026+with+New+Data+Highlighting+Muzastotug%E2%80%99s+Potential+as+a+Backbone+Combination+Therapy+for+Multiple+Tumor+Types/26330503.html Fri, 17 Apr 2026 16:01:00 -0400 ADAG ADAG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Adagene+Inc.++++++++++++++For%3A+Apr+17/26330499.html si-local-file:///var/storage/secattach/20260417/26330499.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Adagene+Inc.++++++++++++++For%3A+Apr+17/26330499.html Fri, 17 Apr 2026 16:00:00 -0400 ADAG O.49875626 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Adagene+Inc.++++++++++++++For%3A+Apr+17/26330499.html si-local-file:///var/storage/secattach/20260417/26330499.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Adagene+Inc.++++++++++++++For%3A+Apr+17/26330499.html Fri, 17 Apr 2026 16:00:00 -0400 ADAG O.49875626 http://www.streetinsider.com/Board+Changes/Adagene+adds+Peter+Lebowitz+to+scientific+advisory+board/26308192.html <p>Adagene Inc. (NASDAQ: ADAG) announced the appointment of Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board. The clinical-stage biotechnology company focuses on developing antibody-based cancer immunotherapies.</p> <p>Lebowitz currently serves as Chief Executive Officer of Third Arc Bio, a clinical-stage biotech company developing multifunctional antibodies for oncology and immunology applications. He previously held the position of Global Head of Oncology R&D at Johnson & Johnson for 13 years, where he led the development organization that delivered 13 new drugs to market with over 60 approvals.</p> <p>During his tenure at Johnson & Johnson, Lebowitz's drug development approach resulted in 12 FDA http://www.streetinsider.com/Board+Changes/Adagene+adds+Peter+Lebowitz+to+scientific+advisory+board/26308192.html Tue, 14 Apr 2026 07:01:04 -0400 A.37819586 ADAG O.00000304 O.49875626 http://www.streetinsider.com/Board+Changes/Adagene+adds+Peter+Lebowitz+to+scientific+advisory+board/26308192.html <p>Adagene Inc. (NASDAQ: ADAG) announced the appointment of Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board. The clinical-stage biotechnology company focuses on developing antibody-based cancer immunotherapies.</p> <p>Lebowitz currently serves as Chief Executive Officer of Third Arc Bio, a clinical-stage biotech company developing multifunctional antibodies for oncology and immunology applications. He previously held the position of Global Head of Oncology R&D at Johnson & Johnson for 13 years, where he led the development organization that delivered 13 new drugs to market with over 60 approvals.</p> <p>During his tenure at Johnson & Johnson, Lebowitz's drug development approach resulted in 12 FDA http://www.streetinsider.com/Board+Changes/Adagene+adds+Peter+Lebowitz+to+scientific+advisory+board/26308192.html Tue, 14 Apr 2026 07:01:04 -0400 A.37819586 ADAG O.00000304 O.49875626 http://www.streetinsider.com/Board+Changes/Adagene+adds+Peter+Lebowitz+to+scientific+advisory+board/26308192.html <p>Adagene Inc. (NASDAQ: ADAG) announced the appointment of Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board. The clinical-stage biotechnology company focuses on developing antibody-based cancer immunotherapies.</p> <p>Lebowitz currently serves as Chief Executive Officer of Third Arc Bio, a clinical-stage biotech company developing multifunctional antibodies for oncology and immunology applications. He previously held the position of Global Head of Oncology R&D at Johnson & Johnson for 13 years, where he led the development organization that delivered 13 new drugs to market with over 60 approvals.</p> <p>During his tenure at Johnson & Johnson, Lebowitz's drug development approach resulted in 12 FDA http://www.streetinsider.com/Board+Changes/Adagene+adds+Peter+Lebowitz+to+scientific+advisory+board/26308192.html Tue, 14 Apr 2026 07:01:04 -0400 A.37819586 ADAG O.00000304 O.49875626